Michael J.Bruner Ph.D.


(T) 1.404.581.8614

Dr. Michael Bruner has more than 15 years of experience representing clients in pharmaceutical and chemical intellectual property matters, such as the development of global patent portfolios to protect their innovations. He guides clients from the early stages of patent portfolio development when leads are initially identified, continuing through the product development process as new filing opportunities arise.

Michael has a Ph.D. in organic chemistry and has extensive experience with patent matters pertaining to chemistry, biochemistry, and pharmaceuticals.

A particular focus of his practice is advising clients with respect to patent life-cycle strategies and regulatory extension opportunities as the portfolio matures and regulatory approval approaches. He also advises clients on due diligence matters, including those relating to clients' investment in or acquisition of third parties, as well as licensing and collaboration opportunities.

A further aspect of Michael's practice is providing clients with opinions relating to patentability, freedom-to-operate, noninfringement, and validity.

Representative clients include Celgene Corporation, PTC Therapeutics, Akebia Therapeutics, Hope Pharmaceuticals, Infinity Pharmaceuticals, Winpak Films, and Brasseler USA. Particular small molecule pharmaceuticals that Michael has been involved with include REVLIMID®, POMALYST®, TranslarnaTM, and Duvelisib. In particular, Michael has been involved with the preparation and prosecution of various patent filings relating to the compounds, as well as applications for U.S. and foreign regulatory extensions.

Prior to attending law school, Michael performed postdoctoral research at the Centers for Disease Control and Prevention (CDC) in the areas of vaccine and infectious diseases.


  • Celgene to be acquired by Bristol-Myers Squibb for approx. $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Celgene establishes global patent portfolio for small molecule pharmaceuticalsOn behalf of Celgene Corporation, Jones Day assisted with global patent prosecution strategy and portfolio development relating to small molecule pharmaceuticals.
  • Signal Pharmaceuticals maintains patent portfolio for small molecule kinase inhibitorsJones Day managed Signal Pharmaceuticals, LLC's patent portfolio and patent prosecution strategies relating to small molecule kinase inhibitors.
  • Georgia-Pacific faces Nat'l Gypsum parent in DJ action over wallboardsJones Day represented Georgia-Pacific Gypsum LLC against New NGC in a declaratory judgment action alleging patent infringement and antitrust claims relating to glass mat-faced gypsum wallboards.
  • Danske Markets and Handelsbanken Capital Markets act as placement agent in €59.3 million rights offering by Danish biopharmaceutical companyJones Day advised Danske Markets and Handelsbanken Capital Markets in a €59.3 million (US$78.4 million) rights offering by LifeCycle Pharma A/S, a Danish biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen.
  • Symphony Capital forms joint venture with Lexicon PharmaceuticalsJones Day advised Symphony Capital Partners, L.P., and its co-investors in connection with a collaborative development agreement with Lexicon Pharmaceuticals, Inc. to establish a joint venture, Symphony Icon Inc. Symphony will provide $65 million in funding to accelerate clinical and other related development activities for three of Lexicon's product candidates: LX6171 for cognitive disorders, LX1031 for irritable bowel syndrome and LX1032 for gastrointestinal disorders.
  • Bioenvision develops patent portfolios for Clolar® and Modrenal®Jones Day assisted Bioenvision, Inc. with the development of patent portfolios and prosecution strategies for Clolar® (clofarabine) and Modrenal®.
  • Nordson acquires Kreyenborg Group's polymer processing companiesJones Day advised Nordson Corporation in its acquisition of Kreyenborg GmbH and BKG Bruckmann & Kreyenborg Granuliertechnik GmbH companies.
  • Esperion establishes patent portfolios for small molecule cholesterol-lowering drugsJones Day represented Esperion Therapeutics, Inc. (later acquired by Pfizer) in establishing its small molecule cholesterol-lowering drug portfolios, prosecuting its peptide portfolio, and prosecuting its liposome cholesterol-lowering portfolio.
  • Additional Publications

    • 2003Evaluation of Synthetic, M type-specific Peptides as Antigens in a Multivalent Group A Streptococcal Vaccine, coauthor, Vaccine 21:2698
    • May 2001Multivalent Peptide Vaccine Against Group A Strep M Proteins Looks Promising, coauthor, Reuters Medical News
    • 2000Use of an Altered Nucleotide Substrate to Unmask the Transition-State for Rat Liver a(2-6) Sialyltransferase, coauthor, Biochemistry 39:2261
    • 1998Isotope Trapping and Kinetic Isotoope Effect Studies of Rat Liver a(2-6) Sialyltransferase, coauthor, Biochemistry 37:289
    • 1998The N-Acetyl Neuraminyl Oxocarbenium Ion is an Intermediate in the Presence of Anionic Nucleophiles, coauthor, J. Am. Chem. Soc. 120:1357
    • 1996Acid-Catalyzed Solvolysis of CMP-NeuAc: Evidence for a Sialyl Cation with a Finite Lifetime, coauthor, J. Am. Chem. Soc. 118:10371
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.